Contact this trialFirst, we need to learn more about you.
MAPK Pathway Inhibitor
JZP815 for Cancer
Recruiting1 awardPhase 1
Chicago, Illinois
This trial is testing JZP815, a new drug, in patients with advanced or metastatic solid tumors that have specific genetic changes. The drug works by blocking signals that promote cancer growth.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service